Galmed Pharma (GLMD) Tops Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. AMZN
2. INTC
3. COIN
4. PINS
5. RDDT
6. FSLR
7. SNDK
8. RIVN
9. SBUX
10. FND

Go back to Galmed Pharma (GLMD) Tops Q1 EPS by 7c

Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results

May 9, 2018 7:00 AM EDT

TEL AVIV, Israel, May 9, 2018 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today provides updated information reaffirming the schedule of the release of the ARREST study top line results and reports financial results for the three months ended March 31, 2018. The Company will host a conference call and webcast at 08:30 a.m. ET... More